Thank you for Subscribing to Life Science Review Weekly Brief
Focusing on developing human-compatible organs and cells, eGenesis appoints Bradford Smith, Chief Financial Officer (CFO) of Homology Medicines Inc., as its independent director.
FREMONT, CA: eGenesis, a gene editing and genome engineering company focusing on developing human-compatible organs and cells, appoint Bradford Smith, Chief Financial Officer (CFO) of Homology Medicines Inc., as an independent director.
“We have recently strengthened our financial position through a $125 million financing, which enables us to aggressively advance our lead kidney and islet cell product candidates towards first-in-human studies,” says Paul Sekhri, President and Chief Executive Officer of eGenesis. “Brad brings deep transactional experience across private and public financings, strategic collaborations, and acquisitions. He will provide a critical perspective to address future funding needs as we remain focused on our mission of solving the global organ shortage.”
Mr. Smith has a long history of successfully executing financial strategies for life science companies, raising nearly $1 billion in equity and debt financing. He led multiple private and public fundraising rounds at Homology Medicines, including an $83.5 million crossover round, a $166 million initial public offering (IPO), a $144 million follow-on financing, and a $60 million equity investment from Pfizer.
Additionally, he was instrumental in the establishment of a collaboration with the Novartis Institute of Biomedical Research. Mr. Smith previously raised nearly $200 million for Ocular Therapeutix through an initial public offering, a secondary offering, and debt financing, as well as negotiating a strategic alliance with Regeneron Pharmaceuticals. Before joining Ocular, he held financial leadership positions at several other healthcare companies, including OmniGuide Surgical, SYNARC, and PatientKeeper, Inc. He began his professional career at Coopers & Lybrand (PWC). Mr. Smith earned a B.S. in Biology from Tufts University and an MBA from New Hampshire's Whittemore School.
“I have always been attracted to ensuring truly innovative life science companies have the financial resources and partners needed to solve huge unmet medical needs,” says Mr. Smith. “eGenesis has the potential to radically improve how we treat organ failure and I look forward to working with the management team and my colleagues on the Board to transform transplantation for patients.”